{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Androgen deprivation therapy",
      "Androgen receptor",
      "Depression",
      "Hypogonadism",
      "Major depressive disorder",
      "Testosterone",
      "Testosterone replacement therapy"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36418656",
  "DateCompleted": {
    "Year": "2023",
    "Month": "01",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "05",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "11",
        "Day": "22"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s11154-022-09767-0"
    ],
    "Journal": {
      "ISSN": "1573-2606",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "6",
        "PubDate": {
          "Year": "2022",
          "Month": "Dec"
        }
      },
      "Title": "Reviews in endocrine & metabolic disorders",
      "ISOAbbreviation": "Rev Endocr Metab Disord"
    },
    "ArticleTitle": "The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing Men.",
    "Pagination": {
      "StartPage": "1259",
      "EndPage": "1273",
      "MedlinePgn": "1259-1273"
    },
    "Abstract": {
      "AbstractText": [
        "Considerable research has shown that testosterone regulates many physiological systems, modulates clinical disorders, and contributes to health outcome. However, studies on the interaction of testosterone levels with depression and the antidepressant effect of testosterone replacement therapy in hypogonadal men with depression have been inconclusive. Current findings indicate that low circulating levels of total testosterone meeting stringent clinical criteria for hypogonadism and testosterone deficiency induced by androgen deprivation therapy are associated with increased risk for depression and current depressive symptoms. The benefits of testosterone replacement therapy in men with major depressive disorder and low testosterone levels in the clinically defined hypogonadal range remain uncertain and require further investigation. Important considerations going forward are that major depressive disorder is a heterogeneous phenotype with depressed individuals differing in inherited polygenic determinants, onset and clinical course, symptom complexes, and comorbidities that contribute to potential multifactorial differences in pathophysiology. Furthermore, polygenic mechanisms are likely to be critical to the biological heterogeneity that influences testosterone-depression interactions. A genetically informed precision medicine approach using genes regulating testosterone levels and androgen receptor sensitivity will likely be essential in gaining critical insight into the role of testosterone in depression."
      ],
      "CopyrightInformation": "\u00a9 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-1509-1868"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA. rhauger@health.ucsd.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Center for Behavior Genetics of Aging, Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA, USA. rhauger@health.ucsd.edu."
          }
        ],
        "LastName": "Hauger",
        "ForeName": "Richard L",
        "Initials": "RL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Behavior Genetics of Aging, Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA, USA."
          }
        ],
        "LastName": "Saelzler",
        "ForeName": "Ursula G",
        "Initials": "UG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Scientist Training Program, School of Medicine, University of California San Diego, La Jolla, CA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Biomedical Science Program, School of Medicine, University of California San Diego, La Jolla, CA, USA."
          }
        ],
        "LastName": "Pagadala",
        "ForeName": "Meghana S",
        "Initials": "MS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Center for Behavior Genetics of Aging, Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA, USA."
          }
        ],
        "LastName": "Panizzon",
        "ForeName": "Matthew S",
        "Initials": "MS"
      }
    ],
    "GrantList": [
      {
        "GrantID": "I01 CX001727",
        "Acronym": "CX",
        "Agency": "CSRD VA",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AG050595",
        "Acronym": "AG",
        "Agency": "NIA NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review",
      "Research Support, N.I.H., Extramural",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Germany",
    "MedlineTA": "Rev Endocr Metab Disord",
    "NlmUniqueID": "100940588",
    "ISSNLinking": "1389-9155"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Androgen Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Androgen"
    },
    {
      "RegistryNumber": "3XMK78S47O",
      "NameOfSubstance": "Testosterone"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aging"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Androgen Antagonists"
    },
    {
      "QualifierName": [
        "genetics",
        "drug therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Hypogonadism"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hypothalamic-Pituitary-Gonadal Axis"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Prostatic Neoplasms"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Receptors, Androgen"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Testosterone"
    }
  ],
  "CoiStatement": "The corresponding author Richard L. Hauger (RLH) has no relevant conflicts of interest to disclose interests that are directly or indirectly related to the work submitted for publication. Ursula G. Saelzler (UGS), Meghana S. Pagadala (MSP), and Matthew S. Panizzon (MSP) have no relevant conflicts to disclose."
}